Csl Ltd - CSLLY STOCK NEWS

CSL Seqirus selected by BARDA to deliver H5N8 A/Astrakhan antigen to the U.S. government for pandemic response readiness

ESC guidelines upgrade recommendations for IV iron supplementation in the treatment of iron deficiency in HF patients, positively impacting CSL Vifor's Ferinject®. IV iron supplementation is recommended to alleviate HF symptoms and improve quality of life. Additionally, results from the HEART-FID trial show a modest benefit in HF outcomes with ferric carboxymaltose. Pooled analysis of long-term trials also demonstrates reduced risks of hospitalization due to HF or cardiovascular causes with ferric carboxymaltose.

CSL, a global biotechnology leader, has appointed Jeffrey Ball as its Chief Sustainability Officer. Ball has been with CSL since 2019 and has played a vital role in the evolution of the company's Sustainability Strategy. As Chief Sustainability Officer, Ball will oversee the expansion and operationalization of key sustainability targets and initiatives. CSL's Sustainability Strategy focuses on Environment, Social and Sustainable Workforce, with strong Governance underpinning all pillars.

CSL Seqirus has begun shipping its portfolio of innovative influenza vaccines across the U.S. for the 2023/24 influenza season. The company aims to supply over 55 million doses to healthcare providers. CSL Seqirus offers differentiated vaccine options approved for individuals aged six months and older. The portfolio includes FLUCELVAX QUADRIVALENT, the first and only cell-based quadrivalent influenza vaccine; FLUAD QUADRIVALENT, the first and only adjuvanted quadrivalent seasonal influenza vaccine for adults 65 years and older; and AFLURIA QUADRIVALENT, an egg-based quadrivalent influenza vaccine. Vaccination rates were low during the previous year, despite a significant increase in influenza cases, especially in children.

CSL Behring announced FDA approval for a 50mL prefilled syringe of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) on April 18, 2023. Hizentra is the first immune globulin available in prefilled syringes, offering convenience for patients with Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The new size expands options for self-administration, decreasing treatment burden. Hizentra remains the most prescribed treatment for PI in the U.S. and is the only one approved for CIDP. Available in early 2024, the new syringe size joins existing 5mL, 10mL, and 20mL versions. CSL Behring aims to meet the anticipated demand for this innovative delivery method.

Tavneos^® has been newly incorporated in the 2022 EULAR recommendations for managing ANCA-associated vasculitis (AAV), according to a recent announcement by Vifor Fresenius Medical Care Renal Pharma. The recommendations highlight Tavneos^® as a key therapy option, emphasizing its ability to reduce glucocorticoid exposure and lower toxic effects while potentially enhancing renal function in GPA/MPA patients. The ADVOCATE study demonstrated that the Tavneos^® regimen surpassed prednisone in achieving sustained remission. This endorsement marks a significant step in enhancing patient care standards for AAV treatment, reflecting a commitment to reducing reliance on glucocorticoids.